AdvisorShares Psychedelics ETF Rating $20.45 +0.58 (+2.92%) As of 05/21/2026 04:10 PM Eastern Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsOwnershipRatingsShort InterestBuy This Stock AdvisorShares Psychedelics ETF Aggregate Rating and Price Target (2026)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.PSIL Aggregate RatingModerate Buy 2.62Holdings in PSIL have an aggregate rating of Moderate Buy based on 188 analyst ratings issued in the past year covering 20 companies (85.9% of the portfolio).PSIL Aggregate Price Target$20.45High Prediction$20.45Average Prediction$20.45Low Prediction$20.45Holdings in PSIL have an aggregate price target of $20.45 and a range of $20.45 to $20.45 covering 20 companies (85.9% of the portfolio).PSIL Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy1 Buy rating(s)Moderate Buy11 Moderate Buy rating(s)Hold3 Hold rating(s)Reduce2 Reduce rating(s)Sell0 Sell rating(s)Strong Sell3 Strong Sell rating(s) Ratings for Stocks Held by AdvisorShares Psychedelics ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 20 PSIL Holdings ExportWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings9.69%CMPSCompass Pathways$11.59+6.6%3.8048 of 5 stars2.92$20.58 77.6%12Analyst Revision9.52%ATAIAtai Beckley$4.33+5.9%3.9744 of 5 stars2.91$16.00 269.5%11Positive NewsAnalyst RevisionGap Up8.86%DFTXDefinium Therapeutics$22.65+8.5%3.1723 of 5 stars3.00$37.92 67.4%158.62%RLMDRelmada Therapeutics$7.21+0.6%2.2863 of 5 stars2.71$12.00 66.4%75.74%GHRSGH Research$21.77-3.4%2.8926 of 5 stars2.73$40.38 85.5%11Analyst ForecastAnalyst RevisionGap Up5.64%NRXPNRx Pharmaceuticals$3.06+3.0%2.7473 of 5 stars2.50$38.25 1,150.0%6Earnings Report4.80%NBIXNeurocrine Biosciences$155.50+0.5%3.7666 of 5 stars2.82$184.15 18.4%22Insider Trade4.43%ANROAlto Neuroscience$21.51+3.5%2.7624 of 5 stars2.67$35.25 63.9%94.09%ALKSAlkermes$36.95-0.1%3.2565 of 5 stars2.76$45.40 22.9%17Analyst Revision3.82%SUPNSupernus Pharmaceuticals$49.38+1.4%3.3283 of 5 stars2.43$62.17 25.9%73.70%ABBVAbbVie$214.86+1.2%4.9102 of 5 stars2.88$253.43 18.0%25Trending News3.57%NEUPNeuphoria Therapeutics$5.12+3.9%2.6434 of 5 stars2.00$21.00 310.2%4Earnings Report3.50%STIMNeuronetics$1.193.2314 of 5 stars2.00$3.00 152.1%2Positive NewsInsider Trade3.47%JNJJohnson & Johnson$231.69+1.0%4.3787 of 5 stars2.74$253.04 9.2%27Trending News1.96%KTTAPasithea Therapeutics$0.72-0.1%2.724 of 5 stars1.67$3.00 316.1%3Positive NewsEarnings Report1.56%PBMPsyence Biomedical$4.06+1.2%1.5776 of 5 stars1.001Positive News1.26%SILOSilo Pharma$0.38+0.9%0.1448 of 5 stars1.0010.68%VTGNVistaGen Therapeutics$0.64-0.4%2.5453 of 5 stars1.80$0.95 49.1%50.52%IGCIGC Pharma$0.29+2.8%1.8696 of 5 stars2.50$5.25 1,717.2%20.49%IXHLIncannex Healthcare$3.64-1.9%0.9363 of 5 stars1.001Positive News This page (NYSEARCA:PSIL) was last updated on 5/22/2026 by MarketBeat.com Staff. From Our PartnersSystem failure: The strongest leverage for gold…$9 trillion in U.S. debt must be refinanced in 2026 - at current rates - while the largest foreign buyers of T...Golden Portfolio | SponsoredI had never heard of this 1888 accountAn investment account dating back to 1888 has quietly delivered average annual returns of 29% over the last 25...The Oxford Club | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | Sponsored"Computers are about to become obsolete" - George Gilder. Here’s why.George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and ...Eagle Publishing | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredSpaceX controls two-thirds of all satellites - and it is about to go publicSpaceX is targeting an IPO on June 11th, with trading set to begin June 12th and the roadshow kicking off June...NXT Wave Research | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredHow to Profit from Elon’s AI lab before it goes publicElon Musk's AI lab has partnered with the Department of Defense, Oracle, and Palantir - and he just filed conf...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AdvisorShares Psychedelics ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share AdvisorShares Psychedelics ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
